Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES)
- DOI
- 10.1016/j.dld.2025.11.003
- Published
- 2026-01
- Container
- Digestive and Liver Disease
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.dld.2025.11.003,
title = {Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES)},
author = {Jérémie H. Lefevre and Olivier Dubreuil and Raphael Colle and David Tougeron and Angélique Vienot and Aurélien Dupré and Clémence Toullec and Denis Smith and Rosine Guimbaud and Benoist Chibaudel and Marie-Line Garcia Larnicol and Dewi Vernerey and Romain Cohen},
year = {2026},
journal = {Digestive and Liver Disease},
doi = {10.1016/j.dld.2025.11.003},
url = {https://doi.org/10.1016/j.dld.2025.11.003}
}RIS
TY - JOUR TI - Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES) AU - Jérémie H. Lefevre AU - Olivier Dubreuil AU - Raphael Colle AU - David Tougeron AU - Angélique Vienot AU - Aurélien Dupré AU - Clémence Toullec AU - Denis Smith AU - Rosine Guimbaud AU - Benoist Chibaudel AU - Marie-Line Garcia Larnicol AU - Dewi Vernerey AU - Romain Cohen PY - 2026 JO - Digestive and Liver Disease DO - 10.1016/j.dld.2025.11.003 UR - https://doi.org/10.1016/j.dld.2025.11.003 ER -
APA
Lefevre, J. H., Dubreuil, O., Colle, R., Tougeron, D., Vienot, A., Dupré, A., Toullec, C., Smith, D., Guimbaud, R., Chibaudel, B., Larnicol, M. G., Vernerey, D., & Cohen, R. (2026). Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES). Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.11.003
Source records
- crossref · retrieved 2026-09-27T01:22:15.878Z